Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype

Abstract Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching tumor samples from a cohort of NSCLC patients sho...

Full description

Bibliographic Details
Main Authors: Stefanie Hiltbrunner, Lena Cords, Sabrina Kasser, Sandra N. Freiberger, Susanne Kreutzer, Nora C. Toussaint, Linda Grob, Isabelle Opitz, Michael Messerli, Martin Zoche, Alex Soltermann, Markus Rechsteiner, Maries van den Broek, Bernd Bodenmiller, Alessandra Curioni-Fontecedro
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40745-5

Internet

https://doi.org/10.1038/s41467-023-40745-5

Similar Items